Deucravacitinib in Moderate Plaque Psoriasis: Efficacy in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Main Article Content

Andrew Blauvelt
Neil J. Korman
Joseph F. Merola
Melinda Gooderham
Eugene Balagula
Rebecca Vanlandingham
Michelle Treitel
Keith Wittstock
Kim Hoyt
Subhashis Banerjee
Seemal R. Desai


deucravacitinib, TYK2, plaque psoriasis


Introduction: Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, was efficacious and well tolerated in adults with moderate to severe plaque psoriasis in the global, 52-week, phase 3 POETYK PSO-1 (NCT03624127) and PSO-2 (NCT03611751) trials. We report clinical efficacy of deucravacitinib in the patient subgroup from these trials with baseline plaque psoriasis of moderate severity.

Methods: PSO-1 and PSO-2 randomized patients with moderate to severe plaque psoriasis (PASI ≥12, sPGA ≥3, BSA involvement ≥10% at baseline) 1:2:1 to oral placebo, deucravacitinib 6 mg once daily, or apremilast 30 mg twice daily. Placebo patients crossed over to deucravacitinib at Week 16 in both trials. In PSO-1, deucravacitinib-treated patients received continuous deucravacitinib through Week 52. In PSO-2, PASI 75 responders at Week 24 on deucravacitinib were rerandomized to placebo or deucravacitinib (1:1) through Week 52. In patients meeting criteria for plaque psoriasis of moderate severity, defined as sPGA 3 and BSA 10%-15% at baseline, in the pooled PSO-1/PSO-2 trials, PSO-1 alone, and the PSO-1 placebo crossover population, deucravacitinib efficacy vs placebo was evaluated by PASI 75, PASI 90, and sPGA 0/1 (clear/almost clear) responses (nonresponder imputation) and PASI change from baseline (mBOCF). The Clopper-Pearson method was used to calculate 95% CIs.

Results: PSO-1/PSO-2 moderate psoriasis subgroup PASI 75 response rates were higher with deucravacitinib vs placebo at Week 16 (49.1% [95% CI, 42.5%-55.7%] vs 11.7% [95% CI%, 5.9%-17.4%]) and continued to increase through Week 24 (63.8% [95% CI, 57.5%-70.1%]). PSO-1 PASI 75 response rates were higher with deucravacitinib vs placebo at Week 16 (54.1% [95% CI, 42.1%-65.7%] vs 12.0% [95% CI, 4.5%-24.3%]), Week 24, and were sustained until Week 52. Week 52 PASI 75 response rates for deucravacitinib and placebo crossover groups were comparable (74.3% [95% CI, 62.8%-83.8%] and 67.4% [95% CI, 51.5%-80.9%], respectively). PASI 90 and sPGA 0/1 response rates and change from baseline PASI followed similar patterns, with marked improvement vs placebo at Week 16; peak responses were observed at Week 24 and sustained through Week 52. Efficacy results were comparable to those previously reported for moderate to severe psoriasis.

Conclusion: Deucravacitinib efficacy was confirmed in moderate plaque psoriasis and was consistent with published data in the PSO-1 and PSO-2 overall study population with moderate to severe plaque psoriasis.




















1. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736.

2. Sotyktu [package insert]. Princeton, NJ, USA: Bristol Myers Squibb; September 2022.

3. Sotyktu [summary of product characteristics]. Dublin, Ireland: Bristol Myers Squibb Pharmaceutical Operations; March 2023.

4. Sotyktu [package insert]. Tokyo, Japan: Bristol Myers Squibb K.K.; September 2022.

5. Sotyktu [product information]. Mulgrave, VIC, Australia: Bristol Myers Squibb Australia Pty. Ltd.; December 2022.

6. Sotyktu [product monograph]. Montreal, QC, Canada: Bristol Myers Squibb Canada Co.; November 2022.

7. Wrobleski ST, et al. J Med Chem. 2019;62:8973-8995.

8. Armstrong AW, et al. J Am Acad Dermatol. 2023;88:29-39.

9. Strober B, et al. J Am Acad Dermatol. 2023;88:40-51.

10. Warren RB, et al. Presented at the 30th EADV Congress, September 29–October 2, 2021.

11. Armstrong AW, et al. JAMA Dermatol. 2013;149:1180-1185.

12. Lebwohl MG, et al. J Am Acad Dermatol. 2014;70:871-881.

13. Elmets CA, et al. JAMA Dermatol. 2019;80:1073-1113. 14. Stein Gold L, et al. Br J Dermatol. 2023;189:540-552.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>